The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Catherine Lai,1 Adrese Michael Kandahari,1 Chaitra Ujjani2 1Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA; 2Seattle Cancer Care Alliance, Fred Hutchinson CRC, University of Washington, Seattle, WA, USACorrespondence: Catherine LaiLombardi Comprehen...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lai C, Kandahari AM, Ujjani C
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://doaj.org/article/8d0f2aa8840b4083b1f665551c3fda37
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Catherine Lai,1 Adrese Michael Kandahari,1 Chaitra Ujjani2 1Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA; 2Seattle Cancer Care Alliance, Fred Hutchinson CRC, University of Washington, Seattle, WA, USACorrespondence: Catherine LaiLombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USATel +1-202-444-3735Fax +1-202-444-0939Email Catherine.lai@gunet.georgetown.eduAbstract: The arrival of the CD30 directed antibody-drug conjugate, brentuximab vedotin (BV), has altered the approach to patients with classical Hodgkin lymphoma. Since initial approval in 2011, BV has been extensively studied in previously untreated and relapsed/refractory patients. Treatment indications for the antibody-drug conjugate have been expanded from the previously treated population to include maintenance therapy after autologous stem cell transplantation and recently, combination with chemotherapy in newly diagnosed advanced stage patients. This article will review the evolution of BV in classical Hodgkin lymphoma, detailing the studies that led to the approved indications and discussion of recent trials in combination with chemotherapy and immunotherapy.Keywords: antibody-drug conjugate, brentuximab vedotin, CD30, immunotherapy, classical Hodgkin lymphoma, novel therapies